Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 8,262 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Age Clear all
Active, not recruiting Phase 2 Interventional Results available

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer

NCT00609791
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, pharmacological study, physiologic testing, questionnaire administration, study of socioeconomic and demographic variables, cognitive assessment, psychosocial assessment and care
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 1:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT03092674
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Azacitidine, Cytarabine, Decitabine, Laboratory Biomarker Analysis, Midostaurin, Nivolumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
506
States / cities
Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 337 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 30, 2026, 1:50 PM EDT
Completed Phase 3 Interventional Results available

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

NCT00023452
View directory record Official record
Conditions
Tuberculosis
Interventions
RPT + INH once weekly for 3 months given by DOT, Isoniazid (INH) daily for 9 months
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
2 Years and older
Enrollment
8,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 30, 2026, 1:50 PM EDT
Completed No phase listed Observational

CNS Qualitative Interview

NCT05219149
View directory record Official record
Conditions
Central Nervous System Cancer
Interventions
Qualitative Interviews
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 1:50 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

NCT00874549
View directory record Official record
Conditions
Meningococcal Infections, Meningococcal Meningitis
Interventions
Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide, Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
56 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
6
States / cities
Scottsdale, Arizona • Bardstown, Kentucky • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 30, 2026, 1:50 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

NCT07587515
View directory record Official record
Conditions
Neovascular (Wet) Age-Related Macular Degeneration
Interventions
EYC-0305
Biological
Lead sponsor
Eyconis INC.
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Beverly Hills, California • Modesto, California • Wake Forest, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 1:50 PM EDT
Completed No phase listed Observational

Natural History of Patients With PH3 and a History of Stone Events

NCT04542590
View directory record Official record
Conditions
Primary Hyperoxaluria Type 3
Interventions
Not listed
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
2 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 30, 2026, 1:50 PM EDT
Recruiting No phase listed Observational

Proximal Risk for Suicide in Adolescents

NCT06400810
View directory record Official record
Conditions
Suicide, Mental Health Issue
Interventions
Analog Devices Inc.
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
13 Years to 17 Years
Enrollment
144 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 1:50 PM EDT
Recruiting Not applicable Interventional

Circadian Light Exposure Adjustment for Restfulness

NCT07391852
View directory record Official record
Conditions
Sleep Onset Latency
Interventions
Amber Tinted Glasses, Clear Glasses, Smart Lightbulbs
Device
Lead sponsor
University of Arizona
Other
Eligibility
60 Months to 83 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 1:50 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Chronic Radiation Cystitis and Effect of Hyperbaric Oxygen Therapy on Patient Reported Outcomes and Urine Inflammatory Biomarkers

NCT07368647
View directory record Official record
Conditions
Radiation Cystitis, Urinary Tract Infection (Diagnosis)
Interventions
Hyperbaric Oxygen Therapy
Other
Lead sponsor
Rachel A. Moses
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 30, 2026, 1:50 PM EDT
Completed Phase 3 Interventional

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)

NCT00050817
View directory record Official record
Conditions
Arteriosclerosis
Interventions
clopidogrel (SR25990)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
45 Years and older
Enrollment
15,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 30, 2026, 1:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

NCT02392468
View directory record Official record
Conditions
Schizophrenia, Alzheimer Disease
Interventions
Placebo matching BI 409306 25 mg, Placebo matching BI 409306 50 mg, BI 409306 25 mg, BI 409306 50 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
La Jolla, California • Eatontown, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 30, 2026, 1:50 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans

NCT05903885
View directory record Official record
Conditions
Colorectal Cancer, Prevention
Interventions
On-site Fecal Immunochemical Test (FIT) Kit Distribution, On-site With Social Media Advertising Fecal Immunochemical Test (FIT) Kit Distribution
Other
Lead sponsor
University of Nebraska
Other
Eligibility
45 Years to 75 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 1:50 PM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 30, 2026, 1:50 PM EDT
Completed No phase listed Observational

Conjoint Analysis of Treatment Preferences for Osteoarthritis

NCT01003925
View directory record Official record
Conditions
Osteoarthritis
Interventions
Standard of care for osteoarthritis treatment, Conjoint Analysis for Osteoarthritis
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
65 Years to 95 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 30, 2026, 1:50 PM EDT
Recruiting Not applicable Interventional

Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families

NCT05268250
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
R2D2 mHealth intervention
Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
8 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 30, 2026, 1:50 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)

NCT01447199
View directory record Official record
Conditions
Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Skin Cancer, Uterus Cancer
Interventions
Health and Diet Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 30, 2026, 1:50 PM EDT
Completed Phase 1Phase 2 Interventional

Building Complex Language

NCT01337232
View directory record Official record
Conditions
Language Development Disorders, Learning Disorders
Interventions
Complex sentence treatment protocol
Behavioral
Lead sponsor
Governors State University
Other
Eligibility
10 Years to 14 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • University Park, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 30, 2026, 1:50 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Kentucky Women's Justice Community Overdose Innovation Network - Phase II

NCT07179614
View directory record Official record
Conditions
Overdose Risk, Opioid Use Disorder, Stimulant Use Disorders
Interventions
Overdose Prevention Intervention Package (OPIP)
Behavioral
Lead sponsor
Michele Staton
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Barbourville, Kentucky • Harlan, Kentucky • Hyden, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 1:50 PM EDT
Completed Phase 2 Interventional

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

NCT00528333
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Lintuzumab (SGN-33), Low dose cytarabine, Placebo
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
60 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Mobile, Alabama • Beverly Hills, California • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Oct 30, 2026, 1:50 PM EDT
Recruiting No phase listed Observational

Early Detection of COPD Exacerbations Using Home Monitoring Device

NCT07554352
View directory record Official record
Conditions
COPD Exacerbation
Interventions
RespirAI
Device
Lead sponsor
RespirAI US Inc
Industry
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 1:50 PM EDT
Completed Not applicable Interventional

Long-Term Outcome Following the Treatment of Pediatric Scoliosis

NCT01760434
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Long-term outcomes
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 99 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 30, 2026, 1:50 PM EDT
Recruiting No phase listed Observational

Computer-based Neurocognitive Assessment in Children With Central Nervous System Tumors Receiving Proton Beam Radiation Therapy

NCT02559752
View directory record Official record
Conditions
Central Nervous System
Interventions
NIH Toolbox Cognitive Battery
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
4 Years to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 30, 2026, 1:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safe Touches: A Rigorous Evaluation of a Sexual Abuse Prevention Program for Children

NCT02181647
View directory record Official record
Conditions
Child Sexual Abuse
Interventions
Safe Touches: Personal Safety Training for Children
Behavioral
Lead sponsor
The New York Society for the Prevention of Cruelty to Children
Other
Eligibility
7 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 30, 2026, 1:50 PM EDT